Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 9Lymphoma, Large B-Cell, Diffuse 8Lymphoma, Follicular 7Rectal Neoplasms 6Lymphoma, Mantle-Cell 6Lymphoma, Large-Cell, Immunoblastic 6Lymphoma, B-Cell, Marginal Zone 6Leukemia, Lymphocytic, Chronic, B-Cell 6Hodgkin Disease 6Congenital Abnormalities 6Colonic Neoplasms 6Burkitt Lymphoma 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Myeloproliferative Disorders 5Multiple Myeloma 5Lymphoma, Non-Hodgkin 5Leukemia, Myeloid, Acute 5Sezary Syndrome 4Mycosis Fungoides 4Lymphoma, T-Cell, Cutaneous 4Lymphoma 4Leukemia, Myeloid, Chronic-Phase 4Leukemia, Myeloid, Accelerated Phase 4Leukemia 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Waldenstrom Macroglobulinemia 3Recurrence 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Neuroblastoma 3

Interventions

Gemcitabine 39Cisplatin 24Oxaliplatin 21Capecitabine 20Fluorouracil 11Leucovorin 9Irinotecan 9130-nm albumin-bound paclitaxel 8durvalumab 6Taxes 5Radiotherapy 5Platinum 4Immunohistochemistry 4Erlotinib Hydrochloride 4Docetaxel 4Carboplatin 4Bevacizumab 4Albumin-Bound Paclitaxel 41,2-diaminocyclohexaneplatinum II citrate 4trifluridine tipiracil drug combination 3Trastuzumab 3Sorafenib 3Observation 3Epirubicin 3Drug Therapy 3tremelimumab 2toripalimab 2regorafenib 2pembrolizumab 2anlotinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Gallbladder Neoplasms × Amplified Fragment Length Polymorphism Analysis × Clear all
NCT00486356 2024-01-03

Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer

University of Nebraska

Phase 1 Completed
46 enrolled
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡